HOW IT IS THOUGHT TO WORK

TRODELVY IS DESIGNED TO WORK DIFFERENTLY THAN TRADITIONAL CHEMOTHERAPIES

Image showing how  TRODELVY® (sacituzumab govitecan-hziy) is thought to work – annotated image
What TRODELVY is made of

Trodelvy is a type of drug called an antibody-drug conjugate, or ADC for short. Unlike traditional chemotherapy, ADCs contain 3 parts: an antibody, an anti-cancer drug, and a linker.

A Antibody

Looks for a specific protein, in this case Trop-2, which is found to be overexpressed in many cancers, including bladder cancer

B Anti-cancer drug

Kills cancer cells once they’re found

C Linker

Connects the anti-cancer drug to the antibody

HOW TRODELVY IS THOUGHT TO ATTACK BLADDER CANCER TUMORS

Scientists discovered that patients with bladder cancer have tumor cells that more often contain the Trop-2 protein. TRODELVY binds to cells with Trop-2.

Information from laboratory studies suggest that this is how TRODELVY works. The clinical benefit of these observations is unknown.

Image showing how  TRODELVY® (sacituzumab govitecan-hziy) is thought to work #1
1. Attaches

The antibody in TRODELVY finds and sticks to the Trop-2 protein

Image showing how  TRODELVY® (sacituzumab govitecan-hziy) is thought to work #2
2. Penetrates

Once attached, TRODELVY delivers an anti-cancer drug directly into the bladder cancer cells

Image showing how  TRODELVY® (sacituzumab govitecan-hziy) is thought to work #3
3. Destroys

TRODELVY kills the bladder cancer cells from within.

Trodelvy is the first ADVANCED BLADDER CANCER TREATMENT
to target THE Trop-2 PROTEIN